Retatrutide
Triple GLP-1/GIP/Glucagon Agonist | Weight Reduction & Diabetes
On this page
What is Retatrutide?
Retatrutide is a lab-made peptide that activates three separate hormone receptors at once, GLP-1, GIP, and glucagon, which is why it's called a triple agonist. Researchers study it for metabolic and weight-management research, and it is currently in late-stage clinical trials rather than approved for sale. Research-grade retatrutide sold here is intended strictly for laboratory study, not for use in people or animals, and is not a substitute for an approved medication.
Key terms:
Retatrutide is a synthetic triple glp-1/gip/glucagon receptor agonist (tri-agonist).
Retatrutide (LY3437943) is a lab-made peptide now in late-stage clinical trials. It acts on three hormone receptors at once: GLP-1 and GIP (gut hormones that influence appetite and blood sugar) and glucagon (which affects how the body burns energy). In the Phase 3 TRIUMPH-1 trial (May 2026), participants on the 12 mg dose averaged 28.3% weight reduction (about 70 lbs) after 80 weeks, and a two-year extension group reached 30.3% (85 lbs). Other 2026 trial data reported a 60.6% drop in sleep-apnea severity scores, and blood sugar returned to the normal range for 46% of participants in a separate diabetes trial. Maker Eli Lilly plans to file for FDA approval in late 2026; a decision is realistically expected in late 2027. Sold strictly for laboratory research use.
Key research areas
- Triple hormone receptor activation associated with 24.2% weight reduction in trials
- Improved glycemic control
- Enhanced cardiovascular benefits compared to single or dual agonists
Researched dosing
This table reflects how researchers structure retatrutide study designs, the titration schedules and dose ranges used in published trials, presented as research methodology, not personal usage guidance.
| Phase | Dose | Frequency | Route |
|---|---|---|---|
| Weeks 1-4, first step | 0.5 mg weekly | Once weekly | Subcutaneous injection |
| Weeks 5-8, second step | 1 mg weekly | Once weekly | Subcutaneous injection |
| Weeks 9-12, third step | 2 mg weekly | Once weekly | Subcutaneous injection |
| Weeks 13-16, fourth step | 4 mg weekly | Once weekly | Subcutaneous injection |
| Weeks 17-20, fifth step | 8 mg weekly | Once weekly | Subcutaneous injection |
| Weeks 21+, highest dose studied | 12 mg weekly | Once weekly | Subcutaneous injection |
| Type 2 diabetes, starting dose | 0.5-1 mg weekly | Once weekly | Subcutaneous injection |
| Type 2 diabetes, maintenance | 4-8 mg weekly | Once weekly | Subcutaneous injection |
| Clinical trial protocol (obesity) | 1-2 mg weekly start | Once weekly | Subcutaneous injection |
How it works
At the cell level, retatrutide research looks at how the compound binds three separate hormone receptors, GLP-1, GIP, and glucagon, at once, a broader activation pattern than single- or dual-receptor compounds.
Triple GLP-1/GIP/glucagon receptor agonist, adding the glucagon receptor on top of the GLP-1/GIP dual-agonist pair is its defining feature versus single- and dual-agonist incretin peptides. Engages GLP-1 for appetite regulation, the GIP receptor for insulin sensitivity, and the glucagon receptor for energy-expenditure signaling and hepatic fat oxidation.
Molecular data
These figures, molecular weight, amino-acid sequence, chain length, are the chemistry basics researchers and lab technicians use to confirm a retatrutide sample's identity and purity before it goes into a study.
- Weight
- 4731.33 Da
- Length
- 39 amino acids
- Type
- Triple GLP-1/GIP/glucagon agonist
His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser
Pharmacokinetics
This chart plots how long a research dose of retatrutide stays active in the literature; its long clearance curve is part of why the clinical trials built on this compound use once-weekly dosing.
- Peak
- 24 hr
- Half-life
- 144 hrs
- Cleared
- ~720 hrs
Phase 2 Clinical Trial Data (Eli Lilly)
What the studies report
This section lists the research areas, including metabolic and weight-management research, that scientists have studied for retatrutide in clinical trials; retatrutide is not yet FDA-approved, and research-grade material sold here is intended for laboratory study only, not human use, and is not a substitute for an approved medication.
Weight Reduction
Clinical trials demonstrate 17.5% at 24 weeks and 24.2% at 48 weeks - highest recorded for any obesity medication in development. Continuous weight reduction throughout trials with no plateau reached at 48 weeks, suggesting greater long-term potential than current therapies. Addresses obesity through appetite suppression, increased energy expenditure, and improved metabolic efficiency via three hormone pathways.
Diabetes
TRANSCEND-T2D-1 Phase III: A1C reductions of 1.7-2.0 percentage points across doses; 46% of 12mg arm reached A1C <5.7% (normoglycemia), 90% <7.0%, 85% <=6.5%.
Cardiovascular
ADA 2026 data: 60.6% AHI reduction in sleep apnea (OSA basket within TRIUMPH-1); knee osteoarthritis basket showed 73.1% WOMAC pain reduction. Cardiovascular benefit profile under ongoing evaluation.
Dosage reference
- Doses used in research
- Published trials started at 0.5-1 mg once weekly. The dose was then raised every 4 weeks, up to 8-12 mg.
- Frequency in studies
- Once weekly
- Handling
- Reconstituted solution, research use only; not for administration
- Timeline reported in studies
- 24-48 hours: appetite suppression; 4-8 weeks: significant weight reduction; 24+ weeks: maximum benefits
- Storage
- Lyophilized powder at room temperature; reconstituted solution refrigerated
- Cycle length
- Continuous therapy - effects reverse upon discontinuation
- Break between cycles
- No cycling required - designed for continuous use
Interactions
This list shows which other metabolic-research peptides scientists study alongside retatrutide, and flags pairings that call for extra caution or monitoring in a research setting.
Reconstitution & storage
This is the standard laboratory method for turning freeze-dried retatrutide powder into a liquid research solution used in published study protocols.
- Remove Retatrutide vial from refrigeration and allow to reach room temperature (15-20 minutes)
- Clean vial top with alcohol swab and allow to air dry completely
- Add calculated amount of bacteriostatic water slowly down the side of the vial to minimize foaming
- Gently swirl the vial in circular motions - DO NOT shake vigorously as this may damage the peptide structure
- Allow to fully dissolve (may take 2-3 minutes) - solution should be clear and colorless
- Store the reconstituted solution refrigerated (2-8°C), labeled with the date and concentration, for laboratory research use only.
Lyophilized: -20°C (long term) · 2-8°C up to 3 months, use within 12-24 months at -20°C
Reconstituted: 2-8°C, use within 28 days
Open the Retatrutide reconstitution calculatorQuality indicators
This section lists what researchers and lab-report reviewers check to confirm a retatrutide sample's purity and identity before it's used in a study.
Pharmaceutical-grade white powder - Lyophilized Retatrutide should appear as a white to off-white powder with uniform texture and no discoloration
Proper cold chain maintenance - Reconstituted solution requires consistent refrigeration at 2-8°C with temperature monitoring
Clear reconstituted solution - Properly reconstituted Retatrutide forms a clear, colorless solution without particles, cloudiness, or precipitates
Stable extended half-life effects - Consistent appetite suppression and metabolic effects between weekly doses indicate proper potency
Source verification critical - Due to investigational status and high demand, counterfeit versions circulate - verify pharmaceutical-grade sourcing
Rapid tolerance or effectiveness loss - Genuine Retatrutide maintains efficacy long-term; rapid tolerance suggests degraded or counterfeit product
Unusual side effect profile - Effects significantly different from expected GI-predominant profile may indicate contaminated or incorrect product
What the lab measured on our batch
This is the store's own test result for the batch of Retatrutide 10mg on the shelf. An outside laboratory ran it, and the report below is the laboratory's own page, not ours. A purity figure is a fact about the powder in the vial. It says nothing about what the compound does.
- Batch
- LXB-RETA-20260701-01
- Purity
- 99.76%
- Lab
- Janoshik Analytical
- Test date
- 2026-07-07
Janoshik Analytical reported a purity of 99.76% for batch LXB-RETA-20260701-01 by HPLC on 2026-07-07. Read the report on the lab's own site , or see every certificate we have published.
What to expect
This timeline reflects what the clinical-trial literature reports at each study stage, research context for comparing studies, not a personal-results promise.
Trials reported initial appetite suppression and mild GI effects during adaptation to triple-receptor activation
Trials reported reduced food cravings and smaller portion sizes with early weight reduction (2-5%)
Trials reported strong appetite control, steady weight reduction (5-10%), and improved glucose control in participants with diabetes
Substantial weight reduction (10-18%) with enhanced energy expenditure and metabolic improvements
Trials reported weight reduction of 15-22% with improving cardiovascular and hepatic-fat endpoints
Peak trial-reported efficacy (20-24.2%) with broad metabolic improvement sustained to trial end
Safety notes
This section summarizes retatrutide's regulatory status and handling notes, research-use-only scope and safety data drawn from the clinical literature, provided as reference context for laboratory researchers, not medical guidance.
- Contraindicated in patients with personal/family history of medullary thyroid carcinoma or MEN2 syndrome
- Monitor for signs of pancreatitis (severe abdominal pain radiating to back) - discontinue immediately if suspected
- Heart rate increases are common - monitor cardiovascular status regularly
- Conservative start at 0.5mg weekly minimizes GI side effects
- Not FDA approved, NDA submission expected Q4 2026; FDA approval realistically late 2027
- Investigational compound, Phase III trials ongoing
Regulatory status
- Not approved by the FDA for any indication.
- Supplied and described for laboratory research use only, not for human or veterinary use.
What is not known
The limits of the published work on Retatrutide, stated plainly. Research use only: none of this is guidance for a person.
Retatrutide is not approved anywhere. Everything on this page is trial data on a compound still being tested.
Two of the three studies in the references below carry no link, because no published paper could be found for them. Headline numbers from a company announcement are not the same thing as a paper anyone can read, and they cannot be checked.
Hitting three receptors at once is the design. Which of the three carries how much of the effect is not known, because these trials did not separate them.
The published trials report what happened while treatment continued. What happens after it stops is not known from them.
The purity figure the lab measured on our batch is a fact about the powder in the vial. It says nothing about whether a compound works, and nothing about safety.
The terms, in plain words
Every technical term this page leans on, said again in ordinary words.
- Triple agonist
- One molecule that flips three different hormone switches at once.
- Glucagon
- A hormone that raises blood sugar and changes how the body burns energy. The opposite number to insulin.
- GIP
- Glucose dependent insulinotropic polypeptide, a gut hormone released after a meal.
- Phase 2 and phase 3
- The middle and last stages of testing before a regulator is asked to approve something.
- A1C
- A blood test showing the average blood sugar over roughly the last three months.
- HPLC
- High performance liquid chromatography, the lab method that separates a sample into its parts so the share that is the intended compound can be measured.
Frequently asked questions
What is Retatrutide?
Retatrutide (LY3437943) is a synthetic triple hormone-receptor agonist that activates three receptors at once, GLP-1, GIP, and glucagon, which is why researchers call it a triple agonist. It is currently an investigational compound in late-stage clinical trials rather than an approved product. Lux BioPure supplies research-grade retatrutide strictly for laboratory study, not for use in people or animals.
What class of compound is retatrutide?
Retatrutide is classified as a synthetic triple GLP-1/GIP/glucagon receptor agonist, a broader activation pattern than single- or dual-receptor compounds. In the research literature this chemistry is characterized by a molecular weight near 4,731 daltons and a 39-residue peptide chain, the kind of figures lab technicians use to confirm a sample's identity and purity before it enters a study.
How is retatrutide typically reconstituted for research use?
In the laboratory, a retatrutide vial is brought to room temperature and its top cleaned with an alcohol swab. Bacteriostatic water is added slowly down the side of the vial to minimize foaming, then the vial is gently swirled, never shaken, until the solution is clear and colorless. This is standard research methodology, not a usage instruction.
How should retatrutide be stored in the lab?
Retatrutide in lyophilized powder form can be held at room temperature per the manufacturer's expiration, while the reconstituted solution is refrigerated near 2-6°C and typically used within about 28 days. Each vial is labeled with its date and concentration for laboratory research use only. A good sample forms a clear, colorless, particle-free solution after gentle mixing.
Is retatrutide legal to purchase for research in Canada?
Lux BioPure sells retatrutide in Canada strictly as a research-use-only chemical for laboratory study, it is not for human or veterinary use and is not offered as a drug or supplement. Retatrutide is not an approved drug; it remains an investigational compound in ongoing Phase III trials, with a regulatory submission anticipated rather than granted.
Sources
The published work behind this entry. Each link was opened and each note says what that paper reports, not what it suggests.
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial New England Journal of Medicine, 2023338 adults, weekly injection at several dose sizes against placebo, for 48 weeks. The trial the later work was built on.
- Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial The Lancet, 2026A 40 week phase 3 trial in adults with type 2 diabetes not controlled by diet and exercise alone.
How it is studied
In the published studies listed below. Each one names the species it was run in, the dose, how long it ran, and what it reported.
OSA basket within TRIUMPH-1: apnea-hypopnea index dropped 36.1 events/hour from baseline 58.6 (60.6% reduction). Knee osteoarthritis basket: 73.1% WOMAC pain reduction. TRANSCEND-T2D-1: 46% of 12mg arm reached A1C <5.7% (normoglycemia).
Pivotal Phase III obesity registration trial (NCT05929066). 12mg achieved 28.3% mean weight reduction (70.3 lbs) at 80 weeks; 9mg 25.9%; 4mg 19.0%. Extension cohort reached 30.3% (85.0 lbs) at 104 weeks. 45.3% of 12mg arm hit >=30% loss.
First Phase III in early type 2 diabetes (NCT06354660). A1C reductions of 1.7-2.0 percentage points; weight reduction up to 16.8% / 36.6 lbs on 12mg. No unexpected safety signals; GI predominant.
View Study